COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn BHBH FPVFPV FLVFLV PVP-IPI REGNR2 LY-CoVLY RMDRMD
Ivermectin study #53 of 65
1/16 Early treatment study
Raad et al., ChiCTR2000033627 (Preprint)
In vivo use of ivermectin (IVR) for treatment for corona virus infected patients (COVID-19): a randomized controlled trial
Source   PDF   Share   Tweet
RCT in Lebanon showing significantly lower viral load at day 3, and lower hospitalization.
Results are from: [1]

Raad et al., 1/16/2021, Single Blind Randomized Controlled Trial, Lebanon, Middle East, preprint, 1 author, dosage 200μg/kg single dose.
risk of hospitalization, 85.7% lower, RR 0.14, p = 0.24, treatment 0 of 50 (0.0%), control 3 of 50 (6.0%), continuity correction due to zero event (with reciprocal of the contrasting arm).
risk of viral load, 59.0% lower, RR 0.41, p = 0.01, treatment 50, control 50, percentage relative improvement in Ct value with treatment at day 3.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 65 studies    Meta analysis
Please send us corrections, updates, or comments.